{
  "docId": "019de073-cc15-73cb-b985-dc28972c4284",
  "docSlug": "df7f4367d54f16f4cdacd02ff486e30b",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 12,
  "pageCount": 31,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/12",
  "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284",
  "deckJsonHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284.json",
  "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.075,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "MAT2203 Oral amphotericin B formulation utilizing LNCs Initial indication in cryptococcal meningitis Efficient intracellular delivery to immune cells and delivery directly to infected tissues",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8af7275f-cc4a-4ebf-bd2a-066335621f2e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.45,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "IMPROVED PROFILE LNC formulation enables oral administration, bioavailability and improved nephrotoxicity over IV amphotericin Demonstrated ability to cross the blood-brain barrier (BBB) with an oral therapy",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4521344-1f57-4313-b3b1-00e88dd9ee0f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.45,
        "y": 0.57
      },
      "kind": "paragraph",
      "text": "POTENTIAL CLINICAL IMPACT Potential to expand the use of amphotericin B beyond treatment of CM to other invasive infections and prophylaxis for immunocompromised (IC) patients Orphan Drug Designation (ODD) + 4 Qualified Infectious Disease (QIDP) and Fast Track Designation",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc9197cf-85c0-47e7-87f8-34f7c7a81c3b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.048,
        "y": 0.075
      },
      "kind": "title",
      "text": "MAT2203: A Novel Approach with a Proven Therapeutic Agent",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a32be7aa-e9f9-4af8-bc76-52e8ccc6e27d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 12,
      "beatId": "89c482f0-3c52-4495-a056-3a361cf054ee",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slide 12 presents MAT2203 as a novel approach",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}